New diabetes clinical trial: Ocular Safety and Usability Study for FYB203 PFS

Published on: November 26, 2024 at 11:00PM
Conditions: Age-Related Macular Degeneration; Branch Retinal Vein Occlusion with Macular Edema; Central Retinal Vein Occlusion with Macular Edema; Diabetic Macular Edema; Diabetic Retinopathy
Interventions: Drug: FYB203 2 mg (0.05 mL of 40 mg/mL)
Sponsors: Formycon AG
Completed
https://ift.tt/X7LWtp1